Home > Insider Trading > Filing (0001209191-23-057725)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
25743	Therapeuticsmd Inc.	TXMD	Pharmaceutical Preparations (2834)	870233535

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1820187	D Marlan Walker	951 Yamato Road Suite 220 Boca Raton FL 33431	Chief Executive Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2023-12-05	70,000	$0.00	81,615	No	4	M	Direct
Common Stock	Disposition	2023-12-06	14,500	$2.31	67,115	No	4	S	Direct
Common Stock	Disposition	2023-12-07	4,550	$2.24	62,565	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2023-12-05	70,000	$0.00	70,000	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	M	Direct

Footnotes

The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $2.22 through $2.48, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices of $2.15 through $2.31, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth.
Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of the issuer. The RSUs vested in full on June 30, 2023.